Benefits of CMAB007 in Chinese Patients Having Inadequately Controlled Moderate/Severe Asthma With Increased Total IgE: A Randomized Phase 3 Trial

  • Kefang Lai
  • , Zhijun Yan
  • , Donghua Qian
  • , Xiaoju Zhang
  • , Tao Bian
  • , Xiaotian Dai
  • , Huiping Li
  • , Lin Lin
  • , Jin Wang
  • , Linwei Wang
  • , Jingping Yang
  • , Yaomin Hu
  • , Hui Li
  • , Xiuhong Nie
  • , Faguang Jin
  • , Guoxiang Li
  • , Shenghua Sun
  • , Feng Xu
  • , Hui Zhao
  • , Yusheng Chen
  • Chuntao Liu, Huili Zhu, Jing Li, Yajun Guo, Nanshan Zhong

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)39-54
Number of pages16
JournalAllergy, Asthma and Immunology Research
Volume18
Issue number1
DOIs
StatePublished - Jan 2026
Externally publishedYes

ASJC Scopus Subject Areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Keywords

  • Asthma
  • IgE
  • antibody
  • asthma exacerbation
  • lung function
  • omalizumab
  • treatment outcome

Cite this